Pets in peril: The relative susceptibility of cats and dogs to procoagulant snake venoms.


Journal

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP
ISSN: 1532-0456
Titre abrégé: Comp Biochem Physiol C Toxicol Pharmacol
Pays: United States
ID NLM: 100959500

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 01 03 2020
revised: 07 04 2020
accepted: 18 04 2020
pubmed: 8 5 2020
medline: 20 2 2021
entrez: 8 5 2020
Statut: ppublish

Résumé

Snakebite is a common occurrence for pet cats and dogs worldwide and can be fatal. In Australia the eastern brown snake (Pseudonaja textilis) is responsible for an estimated 76% of reported snakebite cases to domestic pets nationally each year, with the primary pathology being venom-induced consumptive coagulopathy. While only 31% of dogs survive P. textilis bites without antivenom, cats are twice as likely to survive bites (66%). Even with antivenom treatment, cats have a significantly higher survival rate. The reason behind this disparity is unclear. Using a coagulation analyser (Stago STA R Max), we tested the relative procoagulant effects of P. textilis venom-as well as 10 additional procoagulant venoms found around the world-on cat and dog plasma in vitro, as well as on human plasma for comparison. All venoms acted faster upon dog plasma than cat or human, indicating that dogs would likely enter coagulopathic states sooner, and are thus more vulnerable to procoagulant snake venoms. The spontaneous clotting time (recalcified plasma with no venom added) was also substantially faster in dogs than in cats, suggesting that the naturally faster clotting blood of dogs predisposes them to being more vulnerable to procoagulant snake venoms. This is consistent with clinical records showing more rapid onset of symptoms and lethal effects in dogs than cats. Several behavioural differences between cats and dogs are also highly likely to disproportionately negatively affect prognosis in dogs. Thus, compared to cats, dogs require earlier snakebite first-aid and antivenom to prevent the onset of lethal venom effects.

Identifiants

pubmed: 32376497
pii: S1532-0456(20)30069-7
doi: 10.1016/j.cbpc.2020.108769
pii:
doi:

Substances chimiques

Coagulants 0
Snake Venoms 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108769

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared.

Auteurs

Christina N Zdenek (CN)

Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia. Electronic address: christinazdenek@gmail.com.

Joshua Llinas (J)

Unusual Pets Vets, Jindalee, Brisbane, Australia.

James Dobson (J)

Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia.

Luke Allen (L)

Venom Supplies Pty Ltd, Stonewell Rd, Tanunda, SA 5352, Australia.

Nathan Dunstan (N)

Venom Supplies Pty Ltd, Stonewell Rd, Tanunda, SA 5352, Australia.

Leijiane F Sousa (LF)

Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia; Laboratório de Imunopatologia, Instituto Butantan, São Paulo 05503-900, Brazil.

Ana M Moura da Silva (AM)

Laboratório de Imunopatologia, Instituto Butantan, São Paulo 05503-900, Brazil.

Bryan G Fry (BG)

Venom Evolution Lab, School of Biological Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia. Electronic address: bgfry@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH